FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912962210> ?p ?o ?g. }

• W2912962210 abstract "Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with docetaxel, cisplatin, and 5-FU (TPF) followed by cisplatin and radiotherapy is controversial because of toxicity concerns. The aim of this phase II study was to assess the feasibility of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for LA SCCHN. Patients and Methods: We enrolled patients with histological evidence of squamous cell carcinoma of the oropharynx, hypopharynx, or larynx without distant metastases. IC comprised cisplatin (75 mg/m2) and docetaxel (75 mg/m2) on day 1, repeated every 3 weeks for up to three courses. Cetuximab was initiated at 400 mg/m2, followed by 250 mg/m2 doses weekly until the end of radiotherapy. Radiotherapy (70 Gy/35 fr/7 w) was initiated after the last docetaxel administration. The primary endpoint was the rate of treatment completion. Results: We enrolled 54 patients (median age, 58 years) between August 2013 and October 2015. Our patients were 49 males and 5 females with hypopharyngeal (n = 28), oropharyngeal (n = 19), or laryngeal (n = 7) cancers, and 48 of them had stage IV disease. The overall response rate was 72.2% with a median follow-up of 36.1 months and a 3-year overall survival of 90.7%. The treatment completion rate was 76%; 50 patients (93%) received ≥2 courses of IC, and 41 (76%) completed radiotherapy. The frequencies of grade ≥3 febrile neutropenia or allergy/infusion reactions were 39% and 11%, respectively. There was one treatment-related death. Conclusions: IC with TPEx followed by cetuximab with concurrent radiotherapy showed acceptable compliance for the treatment of LA SCCHN. However, high frequency of febrile neutropenia remains a challenge and further improvement in the management of TPEx is necessary. Trial Registration: UMIN000009928." @default.
• W2912962210 created "2019-02-21" @default.
• W2912962210 creator A5003648443 @default.
• W2912962210 creator A5011675274 @default.
• W2912962210 creator A5014972330 @default.
• W2912962210 creator A5018910129 @default.
• W2912962210 creator A5034582186 @default.
• W2912962210 creator A5035027343 @default.
• W2912962210 creator A5044638012 @default.
• W2912962210 creator A5068369923 @default.
• W2912962210 creator A5076120482 @default.
• W2912962210 creator A5079946853 @default.
• W2912962210 creator A5081561712 @default.
• W2912962210 date "2019-01-22" @default.
• W2912962210 modified "2023-09-23" @default.
• W2912962210 title "A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)" @default.
• W2912962210 cites W1907435746 @default.
• W2912962210 cites W1983970003 @default.
• W2912962210 cites W2010402293 @default.
• W2912962210 cites W2015649106 @default.
• W2912962210 cites W2045248401 @default.
• W2912962210 cites W2080615931 @default.
• W2912962210 cites W2089257078 @default.
• W2912962210 cites W2095029943 @default.
• W2912962210 cites W2096550186 @default.
• W2912962210 cites W2110645520 @default.
• W2912962210 cites W2118938219 @default.
• W2912962210 cites W2141592118 @default.
• W2912962210 cites W2151616125 @default.
• W2912962210 cites W2155384808 @default.
• W2912962210 cites W2158776225 @default.
• W2912962210 cites W2165385965 @default.
• W2912962210 cites W2166349420 @default.
• W2912962210 cites W2171231486 @default.
• W2912962210 cites W2269740635 @default.
• W2912962210 cites W2279336817 @default.
• W2912962210 cites W2286844863 @default.
• W2912962210 cites W2563237334 @default.
• W2912962210 cites W2625675763 @default.
• W2912962210 cites W2901263658 @default.
• W2912962210 cites W2901385432 @default.
• W2912962210 cites W4237233882 @default.
• W2912962210 cites W4384644220 @default.
• W2912962210 doi "https://doi.org/10.3389/fonc.2019.00006" @default.
• W2912962210 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6349830" @default.
• W2912962210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30723701" @default.
• W2912962210 hasPublicationYear "2019" @default.
• W2912962210 type Work @default.
• W2912962210 sameAs 2912962210 @default.
• W2912962210 citedByCount "7" @default.
• W2912962210 countsByYear W29129622102020 @default.
• W2912962210 countsByYear W29129622102021 @default.
• W2912962210 countsByYear W29129622102023 @default.
• W2912962210 crossrefType "journal-article" @default.
• W2912962210 hasAuthorship W2912962210A5003648443 @default.
• W2912962210 hasAuthorship W2912962210A5011675274 @default.
• W2912962210 hasAuthorship W2912962210A5014972330 @default.
• W2912962210 hasAuthorship W2912962210A5018910129 @default.
• W2912962210 hasAuthorship W2912962210A5034582186 @default.
• W2912962210 hasAuthorship W2912962210A5035027343 @default.
• W2912962210 hasAuthorship W2912962210A5044638012 @default.
• W2912962210 hasAuthorship W2912962210A5068369923 @default.
• W2912962210 hasAuthorship W2912962210A5076120482 @default.
• W2912962210 hasAuthorship W2912962210A5079946853 @default.
• W2912962210 hasAuthorship W2912962210A5081561712 @default.
• W2912962210 hasBestOaLocation W29129622101 @default.
• W2912962210 hasConcept C121608353 @default.
• W2912962210 hasConcept C126322002 @default.
• W2912962210 hasConcept C143998085 @default.
• W2912962210 hasConcept C203092338 @default.
• W2912962210 hasConcept C2776530083 @default.
• W2912962210 hasConcept C2776694085 @default.
• W2912962210 hasConcept C2776833033 @default.
• W2912962210 hasConcept C2777063308 @default.
• W2912962210 hasConcept C2778239845 @default.
• W2912962210 hasConcept C2779998722 @default.
• W2912962210 hasConcept C2781190966 @default.
• W2912962210 hasConcept C31760486 @default.
• W2912962210 hasConcept C509974204 @default.
• W2912962210 hasConcept C526805850 @default.
• W2912962210 hasConcept C535046627 @default.
• W2912962210 hasConcept C71924100 @default.
• W2912962210 hasConceptScore W2912962210C121608353 @default.
• W2912962210 hasConceptScore W2912962210C126322002 @default.
• W2912962210 hasConceptScore W2912962210C143998085 @default.
• W2912962210 hasConceptScore W2912962210C203092338 @default.
• W2912962210 hasConceptScore W2912962210C2776530083 @default.
• W2912962210 hasConceptScore W2912962210C2776694085 @default.
• W2912962210 hasConceptScore W2912962210C2776833033 @default.
• W2912962210 hasConceptScore W2912962210C2777063308 @default.
• W2912962210 hasConceptScore W2912962210C2778239845 @default.
• W2912962210 hasConceptScore W2912962210C2779998722 @default.
• W2912962210 hasConceptScore W2912962210C2781190966 @default.
• W2912962210 hasConceptScore W2912962210C31760486 @default.
• W2912962210 hasConceptScore W2912962210C509974204 @default.
• W2912962210 hasConceptScore W2912962210C526805850 @default.
• W2912962210 hasConceptScore W2912962210C535046627 @default.
• W2912962210 hasConceptScore W2912962210C71924100 @default.
• W2912962210 hasLocation W29129622101 @default.
• W2912962210 hasLocation W29129622102 @default.

• next